Forward-Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 . These slides have been.
1. Pooled overall survival and progression-free survival HR were found to be 0.95 and 0.88 for nivolumab/ipilimumab vs. nivolumab. 2. Pooled OR for grade 3-4 adverse events was found to be 1.84 for the combination compared to monotherapy Evidence Rating Level: 1 (Excellent) Study Rundown: Nivolumab/ipilimumab combination therapy has demonstrated improved progression-free survival (PFS) and
Ascentage Pharma s MDM2-p53 Inhibitor APG-115 (Alrizomadlin) Granted an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma, Marking the Twelfth Obtained by the Company prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.